Skip to Content

Advancing Care for Long QT Syndrome.

One Wave at a Time.

Now enrolling: Wave II for LQTS2

🌊

Now enrolling: Wave II for LQTS2 🌊

© 2026 Thryv Therapeutics, Inc. All rights reserved.

Follow our journey

Did you know? 🌍 ~59 million people worldwide are living with atrial fibrillation (AF)—and prevalence continues to rise.

Last week in Amsterdam, our VP, Clinical Research, Alex Brkovic, joined the AF-B-STEP kickoff meeting on behalf of Thryv.

Today is Wear Red Day ❤️
At Thryv, we’re proud to stand together in red to raise awareness of the fight against cardiovascular disease in women – their number one killer. Together, we’re helping shine a light on women’s heart

myQTwave and Wave II are two distinct Long QT Syndrome studies with one shared purpose: advancing patient-centered care.

myQTwave helps us learn from people living with LQTS by tracking symptoms from home, while Wave II evaluates an investigational

Grateful today and every day for the incredible community that supports and strengthens our work in cardiac care. 💛

To the patients, families, advocates, clinicians, scientists, and partners who inspire us—thank you.
Wishing you all a warm, p

Three years ago, the world lost a bright little girl named Isla Hutton to Long QT Syndrome (LQT3). ❤️

At Thryv, Isla’s story — and the love and strength of her father, Dave Hutton (@thelongcutielegacy), who continues to advocate for fami

With FDA IND clearance and backing from leading life sciences investors, Thryv Therapeutics is advancing THRV-1268, our lead SGK1 inhibitor, into Phase 2/3 development for Long QT Syndrome. This combination of regulatory momentum and financing suppor

🚀 Driving science forward at #ESC2025.

Last week, Thryv Therapeutics showcased new preclinical data from a pressure overload (TAC) heart failure model, demonstrating that our lead SGK1 inhibitor, THRV-1268—alone and combined with Jardiance (e

📣 We’re headed to #ESCCongress this weekend! Thryv Therapeutics is proud to announce that we’ll be presenting compelling new preclinical results on our lead SGK1 inhibitor, THRV-1268, at the 2025 European Society of Cardiology Congress i

© Thryv Therapeutics Inc. All rights reserved.